Condition (MeSH)
Neoplasms, Multiple Primary
ClinicalTrials.gov lists 357 trials for Neoplasms, Multiple Primary or a narrower condition beneath it. Novartis Pharmaceuticals has the most among industry and government lead sponsors, with 13.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
1 more section with rows
6 of the 357 trials are tagged with Neoplasms, Multiple Primary itself; the rest are tagged with a narrower condition beneath it.
When did Neoplasms, Multiple Primary trials start? (32)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 32
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 11 |
| 2025 | 15 |
| 2024 | 18 |
| 2023 | 17 |
| 2022 | 28 |
| 2021 | 32 |
| 2020 | 17 |
| 2019 | 13 |
| 2018 | 21 |
| 2017 | 20 |
Showing 10 of 32 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 15 trials starting in 2026 and about 14 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 36 months from start to primary completion across 22 trials still running at the 2026-10-09 snapshot; registered median of 30 months across 223 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Neoplasms, Multiple Primary trials in? (9)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 34 |
| Phase 1/2 | 19 |
| Phase 2 | 43 |
| Phase 2/3 | 8 |
| Phase 3 | 26 |
| Phase 4 | 16 |
| Not applicable | 121 |
| Observational | 88 |
| Expanded access | 2 |
How many Neoplasms, Multiple Primary trials are recruiting? (10)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 6 |
| Recruiting | 43 |
| Enrolling by invitation | 6 |
| Active, not recruiting | 22 |
| Available | 1 |
Showing 5 of 10 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Neoplasms, Multiple Primary trials? (8)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Novartis Pharmaceuticals | 13 |
| Bayer | 12 |
| National Cancer Institute (NCI) | 8 |
| Jazz Pharmaceuticals | 6 |
| National Heart, Lung, and Blood Institute (NHLBI) | 5 |
Showing 5 of 8 sponsors.
Which drugs are being tested for Neoplasms, Multiple Primary? (9)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| EVEROLIMUS | 18 |
| Sirolimus | 13 |
| Elinzanetant | 11 |
| Cannabidiol | 5 |
| FULVESTRANT | 4 |
Showing 5 of 9 drugs.
Interventions as named in the registry (6)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Alpelisib Pill | 3 |
| MK-7075 (miransertib) | 2 |
| Letrozol (Femara, Novartis) | 2 |
| Standard Care | 2 |
| NPC-12G gel | 2 |
Showing 5 of 6 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Neoplasms, Multiple Primary trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Pneumonia | 386 | 14 |
| Angina unstable | 198 | 1 |
| COVID-19 pneumonia | 198 | 3 |
| Angina pectoris | 190 | 4 |
| Coronary artery disease | 182 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Neoplasms, Multiple Primary? (145)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Occult collision tumor of the gastroesophageal junction comprising adenocarcinomas with distinct molecular profiles. | Cancer genetics | 2025 | Yes |
| Genomic characteristics and immune landscape of super multiple primary lung cancer. | EBioMedicine | 2024 | Yes |
| Germline whole genome sequencing in adults with multiple primary tumors. | Familial cancer | 2023 | Yes |
| Clinical features and treatment outcome of lymphoepithelioma-like carcinoma from multiple primary sites: a population-based, multicentre, real-world study. | BMC pulmonary medicine | 2022 | Yes |
| Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma. | European journal of cancer (Oxford, England : 1990) | 2021 | Yes |
Showing 5 of 145 publications.
Sub-conditions in MeSH (3)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.